Stock of the Day

Zoetis (ZTS)

$76.44

-$0.47 (-0.6%)

Market Cap: $32.24B

About Zoetis

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally.

The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.

Zoetis Bull Case

Here are some ways that investors could benefit from investing in Zoetis Inc.:

• The current stock price is around $84, which is significantly lower than its 1-year high of $161.77, potentially offering a buying opportunity for investors looking for value.
• Zoetis Inc. has demonstrated consistent revenue growth, with a recent quarterly revenue increase of 2.9% year-over-year, indicating strong demand for its animal health products.
• The company has a solid dividend yield of 2.8%, providing investors with a reliable income stream, which is particularly attractive in a low-interest-rate environment.
• With a return on equity of 66.85%, Zoetis Inc. shows effective management and profitability, suggesting that the company is generating substantial returns on shareholders' investments.
• The firm has set a positive earnings guidance for FY 2026, projecting earnings per share between 6.850 and 7.000, which reflects confidence in future performance.

Zoetis Bear Case

Investors should be bearish about investing in Zoetis Inc. for these reasons:

• The company recently missed earnings expectations, reporting an EPS of $1.53 compared to the consensus estimate of $1.60, which may raise concerns about its short-term performance.
• Zoetis Inc. has a relatively high debt-to-equity ratio of 2.80, indicating that the company is heavily reliant on debt financing, which could pose risks in a rising interest rate environment.
• There is ongoing legal scrutiny, with a class action lawsuit filed against the company, which could lead to increased legal costs and negatively impact its reputation and stock price.
• The stock has a beta of 0.75, suggesting lower volatility compared to the market, which may not appeal to investors seeking high-growth opportunities.
• Insider trading activity has shown some directors purchasing shares, but the overall insider ownership is only 0.22%, which may indicate a lack of strong confidence from insiders in the company's future prospects.

Recent News

• DEADLINE ALERT for CALX, AVAV, ZTS, LCID: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions (globenewswire.com)
• ZTS Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Zoetis Inc. Securities Lawsuit - Contact The Gross Law Firm (globenewswire.com)
• Zoetis: An Attractive Risk-Reward Opportunity (seekingalpha.com)
• Zoetis Inc. (ZTS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit (prnewswire.com)
• ZOETIS DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Zoetis Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ZTS (globenewswire.com)
• Zoetis Gains as VitalRADS Deal Boosts Diagnostics Narrative (quiverquant.com)
• Bronstein, Gewirtz & Grossman LLC Urges Zoetis Inc. Investors to Act: Class Action Filed Alleging Investor Harm (globenewswire.com)
• SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of July 27, 2026 in Zoetis Inc. Lawsuit - ZTS (prnewswire.com)
• INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zoetis Inc. of Class Action Lawsuit and Upcoming Deadlines - ZTS (prnewswire.com)
• ZOETIS INC. (ZTS) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Zoetis Inc. Investors of Upcoming Deadline (globenewswire.com)